alexa 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment | OMICS International | Abstract
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment

Nicole del Castillo1*, Bridget Zimmerman M2, Billie Tyler3, Vicki L Ellingrod4 and Chadi Calarge5
1Department of Psychiatry, The University of Iowa Hospitals and Clinics, USA
2Department of Biostatistics, The University of Iowa College of Public Health, USA
3Department of Psychiatry, University of Iowa, USA
4Department of Clinical Social and Administrative Sciences, College of Pharmacy, Department of Psychiatry, School of Medicine, University of Michigan, USA
5Department of Psychiatry, The University of Iowa Carver College of Medicine, Psychiatry Research, USA
Corresponding Author : Nicole del Castillo
Department of Psychiatry
The University of Iowa Hospitals and Clinics
200 Hawkins Drive, Iowa City, IA, 52242, USA
Tel: 319-356-1616
E-mail: [email protected]
Received May 17, 2013; Accepted June 27, 2013; Published June 29, 2013
Citation: del Castillo N, Bridget Zimmerman M, Tyler B, Ellingrod VL, Calarge C (2013) 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment. Clin Pharmacol Biopharm 2:110. doi:10.4172/2167-065X.1000110
Copyright: © 2013 del Castillo N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Great inter-individual variability exists in the susceptibility to gain weight during antipsychotic treatment. Thus, we examined whether the -759C/T variants in the promoter region of the 5HT2C receptor gene were differentially associated with weight gain in children and adolescents in long-term risperidone treatment. Methods: Medically healthy 7 to 17 year-olds, treated with risperidone for ≥ six months, were enrolled. Anthropometric measurements, laboratory tests, and treatment history were obtained upon enrollment and from medical records. The effect of the genotype on the trajectory of age-sex-adjusted weight and body mass index (BMI) z scores before and after the onset of risperidone treatment was investigated.
Results: In 124 subjects (90% males, mean age: 11.8 years) treated with risperidone for a mean of 2.8 years, weight and BMI z scores significantly increased after starting risperidone. This change was similar across the two genotype groups as were changes in several cardiometabolic variables.
Conclusion: In contrast to other reports, the T allele failed to confer protection against excessive weight gain or cardiometabolic abnormalities in this group of children and adolescents chronically treated with risperidone.

Keywords

Recommended Conferences

33rd World Congress on Pharmacology

Barcelona, Spain
Share This Page
Top